High-Dose Melphalan Conditioning Benefits Patients With Multiple Myeloma
High-dose melphalan conditioning confers survival benefits in patients with extramedullary and non-extramedullary multiple myeloma.
High-dose melphalan conditioning confers survival benefits in patients with extramedullary and non-extramedullary multiple myeloma.
African Americans benefit from targeted multiple myeloma interventions.
Patients with multiple myeloma who were admitted for gastrointestinal bleeding had higher costs and mortality than those without multiple myeloma.
Social determinants of health create barriers that delay access to expensive oral anti-myeloma drugs for people with newly diagnosed multiple myeloma.
Investigators examined the changes in mortality rates due to COVID-19, influenza, and pneumonia in patients with MM.
The following is a summary of “Association between social determinants of health and time to...
The following is a summary of “Association between financial fragility and treatment patterns...
The following is a summary of “Access to palliative care in patients with multiple myeloma in...
The following is a summary of “Patterns and predictors of electronically measured oral...
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.